RU2594249C2 - Способы и композиции для предотвращения передачи вич-инфекции - Google Patents

Способы и композиции для предотвращения передачи вич-инфекции Download PDF

Info

Publication number
RU2594249C2
RU2594249C2 RU2012142999/15A RU2012142999A RU2594249C2 RU 2594249 C2 RU2594249 C2 RU 2594249C2 RU 2012142999/15 A RU2012142999/15 A RU 2012142999/15A RU 2012142999 A RU2012142999 A RU 2012142999A RU 2594249 C2 RU2594249 C2 RU 2594249C2
Authority
RU
Russia
Prior art keywords
hiv
animal
composition
env
fragment
Prior art date
Application number
RU2012142999/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2012142999A (ru
Inventor
Грант Томас РОУЛИН
Дэмиан Фрэнсис Джон ПУРЦЕЛЛ
Роберт Джон СЕНТЕР
Марит КРАМСКИ
Рой Майкл РОБИНС-БРАУНИ
Готфрид ЛИХТИ
Original Assignee
Иммурон Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммурон Лимитед filed Critical Иммурон Лимитед
Publication of RU2012142999A publication Critical patent/RU2012142999A/ru
Application granted granted Critical
Publication of RU2594249C2 publication Critical patent/RU2594249C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2012142999/15A 2010-04-09 2011-04-11 Способы и композиции для предотвращения передачи вич-инфекции RU2594249C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32239910P 2010-04-09 2010-04-09
US61/322,399 2010-04-09
PCT/AU2011/000407 WO2011123900A1 (en) 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission

Publications (2)

Publication Number Publication Date
RU2012142999A RU2012142999A (ru) 2014-05-20
RU2594249C2 true RU2594249C2 (ru) 2016-08-10

Family

ID=44761932

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012142999/15A RU2594249C2 (ru) 2010-04-09 2011-04-11 Способы и композиции для предотвращения передачи вич-инфекции

Country Status (12)

Country Link
US (1) US20130022619A1 (enExample)
EP (1) EP2555798B1 (enExample)
JP (1) JP6026402B2 (enExample)
CN (1) CN103167881B (enExample)
AP (1) AP3469A (enExample)
AU (2) AU2011238431B2 (enExample)
BR (1) BR112012025678A2 (enExample)
CA (1) CA2795853A1 (enExample)
MX (1) MX343505B (enExample)
RU (1) RU2594249C2 (enExample)
WO (1) WO2011123900A1 (enExample)
ZA (1) ZA201207790B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049524A4 (en) * 2013-09-27 2017-06-14 Duke University Hiv-1 mother-to-child transmission correlates of protection and vaccine
CN103736100B (zh) * 2013-12-25 2017-06-09 南方医科大学 预防hiv性传播的杀微生物剂酸酐修饰抗sevi多克隆抗体
ES2768957T3 (es) * 2015-09-24 2020-06-24 Abvitro Llc Composiciones de anticuerpos contra el VIH y métodos de uso
EP3359838B1 (en) * 2015-10-07 2021-07-21 ECA Medical Instruments Gearless spring torque drive
US10973679B2 (en) * 2016-02-12 2021-04-13 Adam Arreola STD detecting condom
CN116171165A (zh) * 2020-06-10 2023-05-26 墨尔本大学 Hiv-1抗体
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
KR20240007256A (ko) 2021-05-12 2024-01-16 어플라이드 바이오메디컬 사이언스 인스티튜트 이황화 결합된 결합 폴리펩타이드의 스크리닝 및 발현 방법
JP7421610B1 (ja) 2022-08-18 2024-01-24 株式会社マーベラス ゲーム装置
AU2023379740A1 (en) 2022-11-16 2025-05-29 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
US20260092274A1 (en) 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2257198C2 (ru) * 2000-09-28 2005-07-27 Чирон Корпорейшн Композиции микрочастиц и способы их получения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
CA2377479C (en) * 1999-06-24 2011-01-11 Richard B. Markham Compositions and methods for preventing transepithelial transmission of hiv
EP2073840A4 (en) * 2006-10-23 2010-10-27 Progenics Pharm Inc MODIFIED GP140-HOLL-POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERS, COMPLEXES, AND ITS USES
CA2704059A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines
WO2010096042A1 (en) * 2008-10-30 2010-08-26 Dana-Farber Cancer Institute Mimotopes of hiv env

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2257198C2 (ru) * 2000-09-28 2005-07-27 Чирон Корпорейшн Композиции микрочастиц и способы их получения

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOROSKO SM., et al., Induction of HIV-1 MPR(649-684)-specific IgA and IgG antibodies in caprine colostrum using a peptide-based vaccine. Vaccine. 2008 Oct 3;26(42):5416-22. doi: 10.1016/j.vaccine.2008.07.079. Epub 2008 Aug 15. *
HAU J., et al., Refinement of polyclonal antibody production by combining oral immunization of chickens with harvest of antibodies from the egg yolk. ILAR J. 2005;46(3):294-9. *
MANTIS NJ., et al., Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J.Immunol. 2007 Sep 1;179(5):3144-52. *

Also Published As

Publication number Publication date
AU2017265055A1 (en) 2019-06-06
EP2555798A1 (en) 2013-02-13
CA2795853A1 (en) 2011-10-13
AU2011238431B2 (en) 2016-10-06
WO2011123900A1 (en) 2011-10-13
CN103167881B (zh) 2017-06-16
MX2012011574A (es) 2013-03-05
CN103167881A (zh) 2013-06-19
AU2011238431A1 (en) 2012-11-08
EP2555798A4 (en) 2013-11-20
BR112012025678A2 (pt) 2017-07-18
JP2013523783A (ja) 2013-06-17
MX343505B (es) 2016-11-04
ZA201207790B (en) 2013-06-26
RU2012142999A (ru) 2014-05-20
US20130022619A1 (en) 2013-01-24
JP6026402B2 (ja) 2016-11-16
AP2012006519A0 (en) 2012-10-31
AP3469A (en) 2015-11-30
EP2555798B1 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
EP2555798B1 (en) Methods and compositions for inhibiting hiv transmission
RU2407749C2 (ru) Иммуногенная композиция и способ разработки вакцины, основанной на слитом белке
CN110035772B (zh) 水痘带状疱疹病毒疫苗
US7262270B2 (en) Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
WO1999012416A1 (en) T-independent conjugate-vaccines
US20240109956A1 (en) Rapid elicitation of broadly neutralizing bovine antibodies to hiv env
TWI695720B (zh) 藉由針對ｃｄ４之單株抗體調停競爭型ｈｉｖ進入抑制之ｈｉｖ感染的治療和功能性治癒
US20200140529A1 (en) Methods and compositions for inhibiting hiv transmission
AU2021204628B2 (en) Methods and compositions related to accelerated humoral affinity
US20240277829A1 (en) Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
Zinckgraf et al. Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide
Limbert Development of an Effective Chlamydial Vaccine Using Combination Adjuvants
WO2002032452A1 (en) Composition for aids and method producing it
WO2025250861A1 (en) Broadly neutralizing anti-hcmv antibodies and uses thereof
Alonso Galindo Effect of maternal HIV and malaria on the transplacental transfer of antibodies against prevalent pathogens and vaccines in Mozambican women
Vyse et al. P1070 Susceptibility to rubella in females born 1996–2003: a potential congenital rubella syndrome iceberg?
JP2021504478A (ja) 生殖管感染症に対する併用療法と予防
Roodbari et al. P1069 Clustered epitopes within the Gag-env HIV-1 fusion proteins DNA vaccine enhance immune responses in mice
Roodbari et al. P1068 From insects to man: identification of virulence factors involved in the adaptation of the emerging pathogen Photorhabdus asymbiotica to human hosts

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200412